
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is an emerging leader in non-invasive neurostimulation treatments, with a strong financial outlook and potential for international growth. Despite potential risks from competition and market slowdown, the company has a proven track record of success with multiple FDA clearances and a growing presence in the market. The recent FDA clearance for their SWIFT accelerated protocol is expected to drive further growth and increase access to treatment, solidifying their position as a top player in the industry.
Bears say
BrainsWay is a medical device company that has demonstrated the ability to scale a TMS business into sustainable profitability through a high-margin, recurring revenue platform, but its future may be at risk with the potential entry of COMP360 psilocybin therapy and competitors in the neurostimulation market, a low market penetration rate for its products, and the uncertainty of international expansion and Deep TMS 360 success. Despite a strong foundation and positive financials, the potential for disruption and increased competition in the near future warrants a negative outlook on the stock.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares